WallStSmart

Mangoceuticals, Inc. Common Stock (MGRX)vsTempus AI, Inc. Class A Common Stock (TEM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Tempus AI, Inc. Class A Common Stock generates 328948% more annual revenue ($1.36B vs $414,580). MGRX leads profitability with a 0.0% profit margin vs -22.2%. TEM earns a higher WallStSmart Score of 31/100 (F).

MGRX

Avoid

23

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: 2.57

TEM

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 4/9Altman Z: -0.66

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MGRX2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

TEM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
36.1%10/10

Revenue surging 36.1% year-over-year

Areas to Watch

MGRX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.35M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

TEM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Debt/EquityHealth
1.963/10

Elevated debt levels

Price/BookValuation
20.0x2/10

Trading at 20.0x book value

Return on EquityProfitability
-72.7%2/10

ROE of -72.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MGRX

The strongest argument for MGRX centers on Price/Book, Debt/Equity.

Bull Case : TEM

The strongest argument for TEM centers on Revenue Growth. Revenue growth of 36.1% demonstrates continued momentum.

Bear Case : MGRX

The primary concerns for MGRX are EPS Growth, Market Cap, Profit Margin.

Bear Case : TEM

The primary concerns for TEM are EPS Growth, Debt/Equity, Price/Book. Debt-to-equity of 1.96 is elevated, increasing financial risk.

Key Dynamics to Monitor

MGRX profiles as a value stock while TEM is a hypergrowth play — different risk/reward profiles.

TEM is growing revenue faster at 36.1% — sustainability is the question.

MGRX generates stronger free cash flow (-1M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TEM scores higher overall (31/100 vs 23/100) and 36.1% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Mangoceuticals, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Mangoceuticals, Inc. focuses to develop, market, and sell various men's wellness products and services through a telemedicine platform. The company is headquartered in Dallas, Texas.

Visit Website →

Tempus AI, Inc. Class A Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.

Visit Website →

Want to dig deeper into these stocks?